Lung Cancer

Lung cancer starts when cells of the lung become abnormal and start to grow out of control. As more cells develop, they form into a tumor and can spread to other parts of the body. Lung cancer occurs in both smokers and non-smokers, and is more common in women than men. Lung cancer is the leading cause of death in both men and women. There are more treatment options for lung cancer being developed every year, but like most cancers, the earlier it is detected, the better the chance of survival.

Lung Cancer Survival Rates

5-year relative survival for Providence patients is higher than national survival as tracked by the Surveillance, Epidemiology, and End Results (SEER) Program. The survival statistics in the graph below indicate that survival is highest when lung cancer is caught at its earliest stages. The survival rate of patients with any stage of lung cancer treated at Providence exceeds average survival rates nationally.

5-year Relative Survival Rate: Lung Cancer

*See footnote for information on the above survival statistics and methods.

* The Providence patient groups include all patients diagnosed with cancer from 2006- 2012 who received all or part of their initial course of treatment at Providence Cancer Center. The 5-year survival was calculated using Actuarial Survival methods. SEER relative-survival rates used for comparison are also for patients diagnosed from 2006-2012 and follow-up of patients into 2013. These statistics are based on the November 2015 submission of data from the population-based SEER 18 registries and SEER*Stat Database. The survival rates have not been adjusted for age, gender, race/ethnicity or insurance status.

More information on SEER survival statistics and methods ›

Lung Cancer Standards of Care

National Standards of Cancer Care

Patients treated according to national guidelines for cancer care have the best survival rates and quality of life. Providence Cancer Center meets or exceeds the targets set by the Commission on Cancer (CoC).

Commission on Cancer (CoC) Cancer Program Profile Reports (CP3R) Lung Performance Measures

Select Measures CoC Benchmark PPMC 2014 Performance1 PSVMC 2014 Performance1
Systemic chemotherapy is administered within four months to day preoperatively or day-of-surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node positive (pN1) and (pN2) NSCLC (Quality Improvement) 85% 100% 100%
Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement) 85% 94.40% 75.00%
At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage 1A, 1B, 2A and 2B resected NSCLC (Surveillance)       * 89.50% 76.60%

1Most recent data available from the CoC
* No CoC benchmark established at this time